Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Many companies are staking claims in the Clayton Valley, NV. They may have lithium on the property, but getting permits for mining and other processes may winnow them quickly.
Water is a limiting resource is the area. Not every staked claim will achieve success IMO.
Turbo, thanks for the link. These items caught my eye:
The applicant amended the claims and/or description on Jan. 20, 2015. As a result the examination procedure was also amended at the time.
The renewal fees have been paid yearly. The latest for patent year 2015 was paid December 28, 2015. However, the "most Recent Event" of Jan. 8, 2016 says "New entry: Renewal fee paid."
Any ideas on how long these applications take when an amendment is made about two years after the original examination fee was paid?
As a prospective lithium producer LACDF as well as EV car companies have to be very interested in recent Li-S (Lithium sulfur) battery research.
Li-S batteries have the potential to be cheaper, lighter, and safer (no explosions) than Li-ion batteries. If nanotechnology research enables high energy density batteries Li-S to achieve recharge capacity for ten years or more (the big challenge), they are likely to supplant Li-ion batteries as soon as they are tested and certified. For EVs and power grid storage this could be a game-changer IMO.
With such large gains many technical indicators become overbought. Today every Barchart opinion indicator for LA was buy -- that's 100% Buy!
For contrarians like myself this extreme bullishness on a gap up opening is an opportunity to take some profits and lower the basis of my holdings. That's what I did today while remaining bullish.
The LT prospects of LA are better than ever IMO. ST is another matter; we shall see what tomorrow brings.
Can you understand this release about the analyst upgrade?
"Lithium Americas Corp (TSE:LAC) – Analysts at Dundee Securities lifted their FY2018 earnings per share (EPS) estimates for Lithium Americas Corp in a note issued to investors on Monday, according to Zacks Investment Research. Dundee Securities analyst D. Talbot now expects that the brokerage will earn ($0.10) per share for the year, up from their previous estimate of ($0.12). Dundee Securities currently has a “Buy” rating on the stock."
I'm confident about my LT investment in LA, but to me the first paragraph of this release is inaccurate and illogical. Am I missing something?
Tau still showing promise for AZ. What about rare diseases. Staying tuned but ???
http://www.dailymail.co.uk/health/article-3380391/Hope-Alzheimer-s-sufferers-vaccine-removes-tangles-brain-cause-memory-loss.html
Jimmy Carter's cancer gone after immunotherapy drug and radiation treatment.
http://www.myajc.com/news/news/state-regional-govt-politics/in-jimmy-carters-cancer-treatment-drug-could-be-a-/npdN5/?icmp=ajc_internallink_referralbox_free-to-premium-referral
Buz, wasn't payment $1 million for 2 million shares so far in this financing? Target is 3 million shares, so still open.
Anyone with better info please correct me. Also please clarify if additional options or warrants are part of the deal.
Thorny "legal issue" for Shkreli; satirist needles arrested pharma exec.
Lawyer for Martin Shkreli Hikes Fees Five Thousand Per Cent http://www.newyorker.com/humor/borowitz-report/lawyer-for-martin-shkreli-hikes-fees-five-thousand-per-cent … via @BorowitzReport
Makes sense to me. We will see. EOM
Dr. Missler, we trust your leadership of AVXL will avoid this kind of headline:
"High Drug Prices Put Gilead Under Fire From Senate Committee"
https://www.yahoo.com/celebrity/news/high-drug-prices-put-gilead-133916777.html?ref=gs
Martin Shkreli formerly ran a hedge fund; then Turing Pharma. By his financial maneuvers with a decades-old drug which he acquired he became the poster boy for price-gouging. See the Wikipedia article about him, especially the section "Price hike controversy." A Biotech Industry organization expelled Shkreli.
Turing Pharma followed GILD's pricing of their new and highly effective HepC drug. Because of the huge price increases some political/financial leaders have become worried about the ability of government and insurance companies to cover the cost of new drugs.
IMO the takeaway from this is that Dr. Missler and other biotech leaders need to set a new and more sustainable path for drug development and pricing. Having the interests of all stakeholders in view will be increasingly important.
Related research: Some diseases may be caused by misfolding of DNA strands within cell nuclei.
http://news.mit.edu/2015/student-profile-abe-weintraub-1027
Did you read the NYT Oct. 26 article about costs of AZ and dementia care for typical families? The poster gave a link; I read it.
Another $600 a month cost is a heavy added burden.
I also agree about staff numbers. FWIW, the Share Data page on the Co. web site has not been updated since the June 30 SEC filing. Yet up-to-date shares issued and outstanding were given in the recent S3 filing. Fortunately other posters have provided more timely numbers to this MB.
Maybe just a detail, but to me it indicates a need for more hands on deck. Having experienced, qualified people involved at every level is most important. In this regard Dr. Missling has been tops IMO.
Agree! EOM
Not exactly as simple as "market price at company discretion."
The deal is in the details, and it is a typical LPC deal. I've invested in other OTC companies with LPC deals; this is the largest I've seen. I did not see these details addressed among the other good comments about SEC Form 3 filed Oct. 23 on the Lincoln Park Transaction:
"Under the Purchase Agreement, on any business day selected by us, we may direct Lincoln Park to purchase 50,000 shares of our Common Stock on any such business day. On any day that the closing sale price of our common stock is not below $7.00 the purchase amount may be increased, at our sole discretion, to up to75,000 shares of our common stock per purchase; on any day that the closing sale price of our common stock is not below $9.00 the purchase amount may be increased, at our sole discretion, to up to 100,000 shares of our common stock per purchase and on any day that the closing sale price of our common stock is not below $11.00 the purchase amount may be increased, at our sole discretion, to up to 125,000 shares of our common stock per purchase and on any day that the closing sale price of our common stock is not below $13.00 the purchase amount may be increased, at our sole discretion, to up to 150,000 shares of our common stock per purchase. Such purchases are hereinafter referred to as “Regular Purchases”. In no event shall Lincoln Park purchase more than $2,000,000 worth of our common stock pursuant to a Regular Purchase on any single business day. The purchase price per share for each such Regular Purchase will be equal to the lower of:
the lowest sale price for our common stock on the purchase date of such shares; or
the arithmetic average of the three lowest closing sale prices for our common stock during the 10 consecutive business days ending on the business day immediately preceding the purchase date of such shares.
In addition to Regular Purchases described above, we may also direct Lincoln Park, on any business day on which we have properly submitted a Regular Purchase notice, to purchase an additional amount of our Common Stock, which we refer to as an Accelerated Purchase, not to exceed the lesser of:
30% of the aggregate shares of our common stock traded during normal trading hours on the purchase date; and
200% of the number of purchase shares purchased pursuant to the corresponding Regular Purchase.
The purchase price per share for each such Accelerated Purchase will be equal to the lower of:
96% of the volume weighted average price during (i) the entire trading day on the purchase date, if the volume of shares of our common stock traded on the purchase date has not exceeded a volume maximum calculated in accordance with the Purchase Agreement, or (ii) the portion of the trading day of the purchase date (calculated starting at the beginning of normal trading hours) until such time at which the volume of shares of our common stock traded has exceeded such volume maximum; or
the closing sale price of our common stock on the purchase date.
In the case of both Regular Purchases and Accelerated Purchases, the purchase price per share will be equitably adjusted for any reorganization, recapitalization, non-cash dividend, stock split, reverse stock split or other similar transaction occurring during the business days used to compute the purchase price."
Within the past few weeks data center moguls gave their suppliers a direct message about the dilemma they faced in supplying all the data demanded / expected by their customers. As I recall the message posted on this board they floated the idea that they had to give it away for free, or almost free, with increasing demands for more.
Poor us, they seemed to cry, what a business to be in. Who could dare think of charging us much to upgrade our data center capacity, which by the way we need soon in a big way.
Today we found that we can put our crying towels away -- they are doing better than just surviving. LWLG's potential customers are loaded, which as publicly traded companies they had to report.
"Google parent Alphabet Inc (Symbol : GOOG), Microsoft Corp (Symbol : MSFT) and Amazon.com Inc ( Symbol : AMZN) made headway in the latest quarter in the areas that will be their main engines of growth for years to come, driving up shares across the tech sector on Friday.
"Shares of all three surged in early trading, adding more than $120 billion to their combined market value - more than the gross domestic product of Morocco.
"For Alphabet, search traffic on mobiles surpassed desktop traffic worldwide for the first time, while Amazon was able to boost margins, an area of concern, as its cloud business boomed.
"Microsoft's growing emphasis on cloud computing under Chief Executive Satya Nadella also put the company on track successfully transition away from its slowing business that relies on sales of personal computers."
Quoted from Reuters article via Fidelity this AM. Sorry I can't copy URL.
See also: http://www.reuters.com/article/2015/10/23/usa-stocks-idUSL3N12N3SX20151023
Science here looks very promising; awaiting more info.
Other possible fear factors:
1. Valeant Pharma plunge may spread concerns about biotech financing.
2. Joe Biden withdrawal tilts political climate toward HRC who opposes "excess profits" in biotech sector.
3. Several indicators have turned negative on the chart, but are not yet oversold.
I doubt any of these will affect convinced LT holders, but recent buyers above $8.00 may have stops that were hit or may want to limit losses. There are always some vulnerable players in the market.
Could be that day-trader moves were influenced by a huge drop in VRX (Valeant Pharma) early in the day, followed by a late recovery -- much less than AVXLD rebounded.
I use Fidelity. Had 80,000 shares before R/S; now account shows 80 shares.
Huge expectations based on small number of people in early trials are fueling pps surge.
Seven days up in a row, overbought chart indicators, and Barchart bullish opinion at 100% Buy would lead me to expect a pullback soon, but this has a lot of momentum.
Agree it's good to have ILNS noted in a positive way. Still alive with value to be determined, not dismissed.
Also agree with James that the Shire sponsorship is a good sign.
I wonder if you would call today's price action an example of pump and dump?
Although the charts show green volume for the day, the open was at 1.30 and the close at 1.295. But the previous day's close was 1.29, so the close was plus 0.005 for the day. The range for the day was 1.28 to 1.48, and the high was all in the first half hour. Hmmm.
Clay trader didn't comment on AVXL's action today. Although the charts of AVXL and ARWR are different in many respects, the huge drop on 9/26 after a high open for ARWR led Clay Trader to call it a pump and dump day. Today's action by SVXL is ominously similar, even tho it started low and rose to the peak quickly in one trading session.
The sideways closing trend continues. MA trend lines are still rising.
Recent price action in ADXS is another example of rapid price rise to a broker's target after an RS, then a plunge to wipe out recent retail buyers. Big money can hedge positions and cause big adverse moves for longs.
When one's entire retirement rests in a single microcap stock, no matter what the industry group or the compelling story behind the equity, I am amazed.
In my case, and some other MB posters, most of the stories have not had happy (profitable) endings. Why do you think we are still here? We hope AVXL is an exception.
But there's no guarantee, as the risk statements in the SEC filings so plainly state.
Another research report on taupathies
Critical role of acetylation in tau-mediated neurodegeneration and cognitive deficits.
Min SW1,2, Chen X1,2, Tracy TE1,2, Li Y1, Zhou Y1, Wang C1,2, Shirakawa K3, Minami SS1,2, Defensor E4, Mok SA5, Sohn PD1,6, Schilling B7, Cong X7, Ellerby L7, Gibson BW7, Johnson J8, Krogan N8, Shamloo M4, Gestwicki J5, Masliah E9, Verdin E3, Gan L1,2,6.
Author information
Abstract
Tauopathies, including frontotemporal dementia (FTD) and Alzheimer's disease (AD), are neurodegenerative diseases in which tau fibrils accumulate. Recent evidence supports soluble tau species as the major toxic species. How soluble tau accumulates and causes neurodegeneration remains unclear. Here we identify tau acetylation at Lys174 (K174) as an early change in AD brains and a critical determinant in tau homeostasis and toxicity in mice. The acetyl-mimicking mutant K174Q slows tau turnover and induces cognitive deficits in vivo. Acetyltransferase p300-induced tau acetylation is inhibited by salsalate and salicylate, which enhance tau turnover and reduce tau levels. In the PS19 transgenic mouse model of FTD, administration of salsalate after disease onset inhibited p300 activity, lowered levels of total tau and tau acetylated at K174, rescued tau-induced memory deficits and prevented hippocampal atrophy. The tau-lowering and protective effects of salsalate were diminished in neurons expressing K174Q tau. Targeting tau acetylation could be a new therapeutic strategy against human tauopathies.
Tau mentioned in brain study
Study: 95.6 percent of deceased NFL players tested positive for CTE
By John Breech | CBSSports.com
September 18, 2015 8:00 pm ETResearch conducted on almost 100 deceased NFL players revealed that over 95 percent of them tested positive for the degenerative brain disease known as chronic traumatic encephalopathy (CTE).
--------------------------------------
AbstractSend to:
Brain Imaging Behav. 2012 Jun;6(2):244-54. doi: 10.1007/s11682-012-9164-5.
Chronic traumatic encephalopathy: neurodegeneration following repetitive concussive and subconcussive brain trauma.
Baugh CM1, Stamm JM, Riley DO, Gavett BE, Shenton ME, Lin A, Nowinski CJ, Cantu RC, McKee AC, Stern RA.
Author information
Abstract
Chronic Traumatic Encephalopathy (CTE) is a neurodegenerative disease thought to be caused, at least in part, by repetitive brain trauma, including concussive and subconcussive injuries. It is thought to result in executive dysfunction, memory impairment, depression and suicidality, apathy, poor impulse control, and eventually dementia. Beyond repetitive brain trauma, the risk factors for CTE remain unknown. CTE is neuropathologically characterized by aggregation and accumulation of hyperphosphorylated tau and TDP-43. Recent postmortem findings indicate that CTE may affect a broader population than was initially conceptualized, particularly contact sport athletes and those with a history of military combat. Given the large population that could potentially be affected, CTE may represent an important issue in public health. Although there has been greater public awareness brought to the condition in recent years, there are still many research questions that remain. Thus far, CTE can only be diagnosed post-mortem. Current research efforts are focused on the creation of clinical diagnostic criteria, finding objective biomarkers for CTE, and understanding the additional risk factors and underlying mechanism that causes the disease. This review examines research to date and suggests future directions worthy of exploration.
Brain's progression to dementia -- study
http://neurosciencenews.com/mci-dementia-alzheimers-patterns-2676/
Perhaps AVXL issued "so many warrants" because that's they way they could get the financing they needed at the time. The Co. was emerging from pretty rocky financial conditions. Warrants were a "sweetener" for the financing.
Recent filings show that not all warrants have been exercised yet by any means. Probably the warrant holders were significant parties in the rapid stock rise from the $0.30 to $0.50 pps range to the $1.40 to $1.60 pps area earlier this year. Very quickly they could exercise the $0.30 warrants at 4 to 5 times their purchase price (assuming no restrictions), and then hold the rest for much greater upside potential (possibly some warrants still have restrictions).
In any case, the savvy warrant holders quickly lowered the risk of their positions and made possible a nice profit for other longs who wanted shares with very low or no basis going forward.
The buyout of PCYC by ABBV was a part cash, part ABBV stock deal.
Some MB posters were hoping for all stock so that they could control the selling price and presumably benefit from the great value they thought ABBV was getting by the acquisition. The BOD did otherwise.
Did any poster here actually hold PCYC from the dollar area in 2008-2009 through to the recent buyout by ABBV at $257.10? (Disclosure: not me, sorry to say.) Some YB posters say they held PCYC since 2006 -- buying around $4-$5 cost and holding through dips under $1 in 2008 and 2009. Some guts! The LT holders said they were convinced about the science and the CEO's ability to demonstrate its great value (in many indications, BTW).
Do we have enough evidence to project an extraordinary decade for AVXL?
I was too busy to look at the See Thru Equity report until now.
The way I understand the share data, the sum of the shares outstanding, warrants, and stock options is 85.1 million (mn). I consider that the fully diluted shares in a LT perspective.
Please explain in layman's terms why the equity value of FY25E is divided by the present OS of 53.4mn instead of the fully diluted shares of 85.1mn. The DCM Analysis (Page 10) assumes that the warrants will be exercised at the strike price of $0.50, which will help the funding of an important trial. Likely the options would be exercised also. So why would they not be counted in the analysis to arrive at fair value per share? TIA
Coming up on 4 years for Ardueno's patent application based on his research with LWLG (from his private page ajarduengo.net). Maybe it was never supported through the patent process. If it were granted, who might pick up the pieces? Is it moribund? His patents page shows:
"U.S. Patent Appl. 2011/062627
Filed Nov. 31, 2011, - Stable free radical Chromophores and Mixtures thereof, Processes for Preparing the same, Nonlinear Optical Materials, and Uses thereof in Nonlinear Optical Applications (with F. J. Goetz, Sr., A. Ashton, F. J. Goetz, Jr., D. F. Eaton, H. E. Simmons, III, and J. W. Runyon)."
Fully diluted shares 165,548,074 as of June 30, 2015. On Anavex.com / Investors / Share Data. Google finance, Yahoo finance, and otcmarkets.com all lag the company's own disclosure, which adds in debentures, options, and warrants that are not yet issued. Yet they are going to be issued, so are impending dilution.
Kudos to Anavex for giving investors a more realistic view of dilution than the capital stock already issued figure in the latest 10-Q SEC filing. The other sources use that figure, which is of course accurate, but only gives part of the picture.
Could Lightwave do solar? No IP patent yet, and innovations are staking out the field.
http://blog.bccresearch.com/new-method-of-harnessing-solar-power-could-lead-to-inexpensive-efficient-metal-based-solar-cells
Industry info: Venture capital investments in biotech at a 15 year high.
http://blog.bccresearch.com/biotech-is-poised-for-flight-as-venture-capital-lifts-its-wings.-but-will-it-crash
Large number of drilled but not yet hydraulically fractured wells means good prospects for Hectatone sales in U.S.
"What we're observing is U.S. producers are not indicating any decrease in U.S. oil production," Lynn Helms, the director of the [North Dakota] state agency, told reporters Friday. "Even if the price has dropped, they are finding ways to cut costs and to be a lot more efficient with their drilling and completions, and they've built up a very large number of non-completed wells."
That said, production from North Dakota's resource-rich Bakken shale has slowed considerably lately, with just 8,600 barrels added in June — which averaged 1.21 million barrels a day — compared to May, according to the state's numbers.
But with 848 wells drilled but not yet producing, and a "relatively stable" drilling-rig count lately, Helms doesn't expect production to decline.
"I think there's some conflict there," he said. "EIA as well as OPEC have consistently underestimated the resiliency of the North American shale plays. Most of the decline they've projected is supposed to come from the Permian and Eagle Ford (shale basins), not from the Bakken."
But the Permian and Eagle Ford basins, both in Texas, have as many or more non-completed wells than the Bakken — wells that have already been drilled but not yet hydraulically fractured to produce oil.
"It's going to be very resistant to declining prices, production, that is," Helms said."
Selected from: http://www.usatoday.com/story/money/columnist/2015/08/14/loveless-north-dakota-oil/31733073/
Do we know if anyone will represent ILNS at any of these conferences?
CNS Diseases World Summit (September 9-11, 2015, Philadelphia, PA).
The conferences consists of two parts:
Wed - Thurs: 9th Neurodegenerative Conditions Research & Development
Thurs - Fri: 8th CNS Partnering & Deal-Making
Expected number of delegates: 251–500
Abstract submission by August 14, 2015
Alzheimer's Disease and Tau: Pathogenic Mechanisms and Therapeutic Approaches
18 September 2015 in New York.
Abstract submission by 14 August 2015
16th INTERNATIONAL CONFERENCE ON ALZHEIMER'S DRUG DISCOVERY
5–6 October 2015 Jersey City
Abstract submission by September 4, 2015
Nice charts. Some indicators show pullback to a support level with possible reversal of uptrend if price decline continues.
Expanding your top chart to three days also looks like a head-and-shoulders top may be forming. Any way to gauge future moves -- probabilities?